Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan

Journal of Clinical Oncology

Volumn 27, Issue 15, 2009, Pages 2457-2465

  Cecchin, Erika ^a   Innocenti, Federico ^a   D'Andrea, Mario ^a   Corona, Giuseppe ^a   De Mattia, Elena ^a   Biason, Paola ^a   Buonadonna, Angela ^a   Toffoli, Giuseppe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; IFL PROTOCOL; PHENOL GLUCURONOSYLTRANSFERASE; TUMOR MARKER; UDP-GLUCURONOSYLTRANSFERASE 1A9; UGT1A7 PROTEIN, HUMAN;

ADULT; ALLELE; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG GLUCURONIDATION; DRUG RESPONSE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UGT1A1 GENE; UGT1A7 GENE; UGT1A9 GENE; VOMITING; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG RESISTANCE; GENE LINKAGE DISEQUILIBRIUM; GENETICS; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; LEUCOVORIN; LINKAGE DISEQUILIBRIUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 66349133649     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.0314     Document Type: Article

References (28)

1. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002 (Pubitemid 34982202)
2. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004 (Pubitemid 41103619)
3. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8:278-288, 2008 (Pubitemid 352038307)
4. Toffoli G, Cecchin E, Corona G, et al: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068, 2006 (Pubitemid 46638941)
5. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000 (Pubitemid 32059164)
6. Rouits E, Boisdron-Celle M, Dumont A, et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159, 2004 (Pubitemid 39099790)
7. Innocenti F, Ratain MJ: Pharmacogenetics of irinotecan: Clinical perspectives on the utility of genotyping. Pharmacogenomics 7:1211-1221, 2006 (Pubitemid 46024184)
8. Innocenti F, Grimsley C, Das S, et al: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733, 2002 (Pubitemid 36054939)
9. Innocenti F, Liu W, Chen P, et al: Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 15:295-301, 2005 (Pubitemid 40676550)
10. Gagné JF, Montminy V, Belanger P, et al: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617, 2002 (Pubitemid 36329379)
11. Yamanaka H, Nakajima M, Katoh M, et al: A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14: 329-332, 2004 (Pubitemid 38638920)
12. Girard H, Court MH, Bernard O, et al: Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515, 2004 (Pubitemid 39100002)
13. Ramírez J, Liu W, Mirkov S, et al: Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos 35:2149-2153, 2007 (Pubitemid 350146199)
14. Ando M, Ando Y, Sekido Y, et al: Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 93:591-597, 2002 (Pubitemid 34752917)
15. Fujita K, Ando Y, Nagashima F, et al: Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60:515-522, 2007 (Pubitemid 47084262)
16. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244, 2006
17. Lankisch TO, Schulz C, Zwingers T, et al: Gilbert's Syndrome and irinotecan toxicity: Combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 17:695-701, 2008
18. Guillemette C, Ritter JK, Auyeung DJ, et al: Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: Functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644, 2000 (Pubitemid 30769712)
19. Guo SW, Thompson EA: Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48:361-372, 1992
20. Douillard JY, Sobrero A, Carnaghi C, et al: Metastatic colorectal cancer: Integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 14:7-12, 2003 (suppl 2)
21. Strassburg CP, Strassburg A, Nguyen N, et al: Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 338:489-498, 1999 (Pubitemid 129512275)
22. Strassburg CP, Oldhafer K, Manns MP, et al: Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220, 1997 (Pubitemid 27349612)
23. Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290-1295, 2007 (Pubitemid 47394168)
24. Cummings J, Boyd G, Ethell BT, et al: Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 63:607-613, 2002 (Pubitemid 34457694)
25. Cummings J, Ethell BT, Jardine L, et al: Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: Reversal of resistance by food additives. Cancer Res 63:8443-8450, 2003 (Pubitemid 37553155)
26. Cummings J, Zelcer N, Allen JD, et al: Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: Contribution of drug transport proteins. Biochem Pharmacol 67:31-39, 2004 (Pubitemid 37518532)
27. Gagnon JF, Bernard O, Villeneuve L, et al: Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 12:1850-1858, 2006
28. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247-1254, 2007 (Pubitemid 46640571)